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???????
??????????：Inflammatory cytokines have been reported to play important roles in the pathogenesis of 
interstitial lung diseases. However, their individual roles in idiopathic interstitial pneumonitis （IIP） and in 
the other types of interstitial pneumonitis （IP）, including collagen vascular disease associated interstitial 
pneumonitis （CVD-IP）, remain unknown. In this study, we measured the bronchoalveolar lavage （BAL） 
fluid levels of several cytokines in patients with IIP and CVD-IP.
???????：Cell subpopulations in BAL fluid were counted, and BAL fluid levels of interleukin （IL）-2, -6, 
-7, -8, -17, interferon （IFN）-g , tumor necrosis factor （TNF）-a , and transforming growth factor （TGF）
-b 1 were measured using a bead suspension array or an enzyme-linked immunosorbent assay （ELISA） kit 
in 16 patients （8 men, 8 women；mean age, 60.0±9.9 years） with idiopathic nonspecific interstitial pneu-
monitis （NSIP）, 5 patients （3 men, 2 women；mean age, 69.0±4.8 years） with idiopathic usual interstitial 
pneumonitis （UIP）, 5 patients （3 men, 2 woman；mean age, 66.3±5.5 years） with rheumatoid arthritis in 
CVD-IP （RA）, and 5 patients （3 man, 2 women；mean age, 52 .3±14.5 years） with dermatomyositis in 
CVD-IP （DM）, and 13 patients （3 men, 10 women；mean age, 51.8±17.2 years） with sarcoidosis.
???????：BAL cell subpopulations had high amounts of lymphocytes in NSIP and sarcoidosis, and neutro-
phils in RA. Levels of IL-7 were significantly （P＜0.05） higher in DM （9.2±2.2 pg/ml） than in RA （4.5±
1.7 pg/ml）. IL-7 in DM was significantly （P＜0.05） correlated with lymphocytes. The levels of TNF-a  were 
highest for RA （18.6±29.5 pg/ml）, compared with other IPs （1.6±0.7 pg/ml in UIP, 1.8±2.7 pg/ml in NSIP, 
4.4±4.5 pg/ml in DM）, and sarcoidosis （5.8±6.1 pg/ml）. In addition, the levels of IL-17 were highly detect-
able in RA （2.5±2.5 pg/ml）, but not in NSIP, UIP, or sarcoidosis.
???????????：Differences in the cell types of BAL fluid and the level of each cytokine between patients 
with IIP and CVD-IP might reflect pathogenesis and be useful for diagnosis.
???? ????： BAL fluid, cytokine, NSIP, UIP, CVD-IP, sarcoidosis
????????
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????????????
The classification of idiopathic interstitial pneumonia 
（IIP） includes seven clinico-radiologic-pathologic enti-
ties. Usual interstitial pneumonia （UIP） and nonspecif-
ic interstitial pneumonia （NSIP） are the largest sub-
sets of IIP1〜3）. NSIP is distinguished histologically from 
UIP by a temporal uniformity of interstitial inflamma-
tion and/or fibrosis1〜3）. The distinction between NSIP 
and UIP is important for clinical decision making be-
cause prognosis is generally good and the response to 
corticosteroids and immunosuppressants is also good 
in patients with NSIP compared with UIP1〜3）. It is well 
known that NSIP has a relative degree of lymphocyto-
sis with a predominance of CD8 T cells in bronchoal-
veolar lavage （BAL） fluid compared with UIP4〜6）. An 
association between lymphocytosis and levels of inter-
leukin （IL）-6 in BAL fluid of patients with NSIP has 
also been reported5）. In addition, the level of regulated 
upon activation, normal T-cell expressed, and secreted 
（RANTES） in BAL fluid was higher in patients with 
NSIP than in healthy volunteers and in those with UIP 
or sarcoidosis. These findings suggest that NSIP has a 
different pathogenesis from that of UIP but remains 
definitively unclear. Furthermore, although correla-
tions are well known to exist between collagen diseas-
es, such as rheumatoid arthritis, systemic sclerosis, 
dermatomyositis, and lung lesions including interstitial 
pneumonia7〜9）, the pathogenesis of these conditions re-
mains unclear. Several studies have reported that in-
flammatory cytokines, such as IL-1b , IL-2, tumor ne-
crosis factor （TNF）-a , interferon （IFN）-g , and IL-8, 
are involved in collagen vascular disease-associated 
with interstitial pneumonia （CVD-IP） as well as in 
IIP10〜13）. However, the association between cytokine 
pattern and disease features of interstitial pneumonia 
remains unknown.
In this study, we measured the BAL fluid levels of 
IL-2, -6, -7, -8, -17, IFN-g , TNF-a , and transforming 
growth factor （TGF）-b 1 in patients with NSIP, UIP in 
IIP, and CVD-IP in patients with rheumatoid arthritis 
and dermatomyositis, with sarcoidosis, to determine 
the likelihood of a distinct cytokine profile for these 
diseases and to evaluate the correlations between BAL 
cell populations and the investigated cytokines.
???????
Patients
Subjects were patients at the Dokkyo Medical Uni-
versity School of Medicine Hospital and consisted of 5 
patients with idiopathic UIP （3 males and 2 females；
mean age, 69 .0±4.8 years；age range 61–76 years）, 
16 with idiopathic NSIP （8 males and 8 females；mean 
age, 60.0±9.9 years；age range 45–71 years）, 5 with 
CVD-IP （rheumatoid arthritis （RA）） （3 males and 2 
females；mean age, 676.3±5.5 years；age range 60–
70 years）, 5 with CVD-IP （dermatomyositis （DM）） （3 
males and 2 females；mean age, 52.3±14.5 years；age 
range 43–69 years）, and 13 with pulmonary sarcoido-
sis （3 males and 10 females；mean age, 51 .8±17 .2 
years；age range 23–70 years） （Table 1）.
None of the patients had received steroid therapy at 
the time of clinical sample collection. Patients with can-
cer in any organ and those suspected to have malig-
nancy were excluded from the study, and no malignan-
cies were detected in any patient during the study. 
Diagnosis was confirmed pathologically by lung biopsy 
in patients with IIP and CVD-IP, and with sarcoidosis 
as a disease control. Patients with IP associated with 
collagen vascular diseases diagnosed clinically were in-
cluded as RA and DM. Diagnosis of RA was clinically 
established based on the American College of Rheuma-
tology/European League Against Rheumatism14）. Mus-
cle biopsy samples from patients newly diagnosed with 
active DM, according to the classification system of 
Bohan and Peter15 ,16）, were evaluated. Patients with 
sarcoidosis with pulmonary lesions were also enrolled. 
Diagnosis was clinically established based on the path-
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??????????????????：
　 IIP：idiopathic interstitial pneumonia, IP：interstitial pneumonia, NSIP：nonspecific interstitial pneumo-
nia, UIP：Usual interstitial pneumonia, CVD-IP：collagen vascular disease-associated with interstitial 
pneumonia, RA：rheumatoid arthritis, DM：dermatomyositis, BAL：bronchoalveolar lavage, ELISA：
enzyme linked immune assay, TGF-b：transforming growth factor-b , TNF：tumor necrosis factor
BAL fluid in patients with interstitial pneumonia
ological findings of noncaseous epithelioid cell granulo-
mas in lung biopsy samples17）.
The study protocol was approved by the Human 
Ethics Review Committee of Dokkyo Medical Universi-
ty, and a signed consent form was obtained from each 
subject.
Bronchoalveolar lavage
BAL fluid samples were obtained from all subjects 
using a flexible fiberoptic bronchoscope （Olympus 1T-
200, Olympus, Tokyo, Japan） after local anesthesia of 
the upper airway with 4％ lidocaine as described pre-
viously18）. Briefly, the bronchoscope was wedged for 
lavage into one of the subsegmental bronchi of the 
right middle lobe or, in patients with peripheral opaci-
ties, into areas of lung parenchyma otherwise abnor-
mal on chest radiograph. BAL was performed three 
times using a 50-ml aliquot of sterile physiologic saline 
solution. BAL fluid was passed through two sheets of 
gauze and centrifuged at 500×g for 10 min at 4℃ . 
The BAL fluid was centrifuged at 500×g for 5 min, 
and the supernatant was stored at −80℃ for further 
quantification of noncellular components. After wash-
ing twice with phosphate buffered saline solution, cells 
were suspended with 10％ heat-inactivated fetal calf 
serum and counted using a haemocytometer. Differen-
tial cell counts were determined from cell suspensions 
displayed on slides using a cytocentrifuge （Cytospin 
2；Shandon Instruments；Sewickley, PA）. Cells were 
dried, fixed on the slide, and stained by the May-Grün-
wald-Giemsa method. Two hundred cells were identi-
fied under a photomicroscope.
Measurement of IL-2, -6, -7, -8, -17, IFN-g , TNF-
a , and TGF-b 1 in BAL fluid
BAL fluid samples were concentrated by Cen-
triprep-3 （Millipore Corporation；Billerica, MA）, 
which is used to concentrate low-molecular-weight 
components. The cut-off value for molecular weight 
was 3000 Da. In this procedure, magnification of con-
centration was calculated by the ratio of protein con-
sistency in nonconcentrated BAL fluid to that in con-
centrated BAL fluid, which was measured by assay 
（DC protein Assay；Bio-Rad Laboratories；Hercules, 
CA）, and the original levels of cytokines were correct-
ed according to this ratio19）. Since BAL has a dilutional 
effect on the recovery of cytokines, measurements are 
occasionally standardized to albumin. A good correla-
tion with IL-6 （R＝0.78, P＜0.05） and TNF-a  （R＝
0.76, P＜0.05） was observed between the nonstandard-
ized and standardized values by albumin concentra-
tions in BAL fluid of 5 patients with CVD-IP （RA） 
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???????　 Clinical characteristics of patients with UIP, NSIP, CVD-IP（RA）, CVD-IP（DM）, and sarcoidosis. Data are 
presented as mean±SD values.
Sex 
Male/Female Age
（mean±SD）
BAL 
Total cells
（×105/ml）
Eo
（％）
Ly
（％）
Neu
（％）
MF
（％）
Serological 
analysis
LDH（IU/L）
（200-400）
KL-6
（U/mL）
（＜500）
SPD
（ng/mL）
（＜110）
NSIP
8/8
60.0±9.9 years
3.8±2.0 5.6±9.6 25.5±21.4 10.0±10.0 56.4±27.6 372.5±159.8 2175.4±1460.9 308.5±188.8
UIP
3/2
69.0±4.8
4.5±2.5 5.8±7.1 12.0±8.9 11.3±13.7 70.2±18.5 389.8±185.0 1442.1±697.2 295.2±131.6
CVD-IP
（RA）
3/2
66.3±5.5
3.3±2.0 3.9±3.1 18.9±9.4 26.6b±21.3 49.8±20.8 480.5±102.2 1347.8±1058.2 236.5±140.8
CVD-IP
（DM）
3/2
52.3±14.5
3.3±1.1 0.7±1.2 14.9±5.5 5.2±5.2 77.9±2.9 1145.3c±408.8 2289.3±2784.7 178.9±161.2
Sarcoi-
dosis
3/10
51.8±17.2
3.8±1.9 1.5±2.1 48.9a±14.8 1.5±3.8 47.6±14.9 301.8±86.4 754.6±741.9 175.0±118.8
aP＜0.05, compared with UIP and CVD-IP. bP＜0.05, compared with CVD-IP （DM） and sarcoidosis. cP＜0.05, compared with 
the other IPs. Eo：eosinophils；Ly：lymphocytes；Neu：neutrophils；MF：macrophages；LDH：lactate dehydrogenase；
KL-6：Krebs von den lungen；SPD：surfactant protein D.
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（data not shown）, so the cytokine levels reported in 
the text are those of measured concentrations rather 
than those relative to albumin concentrations.
BAL fluid levels of IL-2, -6, -7, -8, -17, IFN-g , and 
TNF-a  were measured using a bead suspension array, 
and the detection limits were 0 .2 pg/ml. In addition, 
concentrations of TGF-b 1 were measured using ELI-
SA kits （R&D, Minneapolis, MN）, as per manufacturer 
instructions. The detection limit was 31.2 pg/ml.
Statistical analysis
Data are expressed as mean±SD values. Differences 
between multiple groups were compared by one-way 
analysis of variance. Fisher’s PLSD test was used as 
the post hoc test. Spearman’s rank correlation analysis 
was used to examine relationships. Statistical analysis 
was performed using JMP software （SAS Institute, 
Inc., Cary, NC）. Statistical significance was defined by 
a P value of less than 0.05.
???????
Differential serological results and cell count of BAL 
fluid
Table 1 shows serological results and the subpopula-
tions of cells in BAL fluid in all subjects. In serological 
analysis, lactate dehydrogenase （LDH） levels were sig-
nificantly （P＜0.05） higher in CVD-IP （DM） than in 
the other IPs and in sarcoidosis. Levels of Krebs von 
den Lungen （KL）-6 tended to be high for NSIP and 
CVD-IP （DM）, compared with UIP, CVD-IP （RA）, 
and sarcoidosis. Levels of surfactant protein D （SPD） 
tended to be high for NSIP and UIP, compared with 
CVD-IP （DM）, and sarcoidosis. Increased LDH levels 
in CVD-IP （DM） were thought to include muscle en-
zyme induced by the disease activity.
In the subpopulations of BAL fluid cells, the percent-
age of lymphocytes was significantly （P＜0.05） higher 
in sarcoidosis than in UIP and CVD-IP （DM）. The 
percentage of lymphocytes tended to be high for NSIP 
compared with UIP. The percentage of neutrophils 
was significantly （P＜0.05） higher in CVD-IP （RA） 
than in CVD-IP （DM）, and sarcoidosis. On the other 
hand, subpopulations of eosinophils were not signifi-
cantly increased among these diseases.
BAL fluid levels of IL-2, -6, -7, -8, -17, IFN-g , 
TNF-a , and TGF-b 1
We measured the levels of IL-2 , -6 , -7 , -8 , -17 , 
IFN-g , TNF-a , and TGF-b 1 （Figure 1 A, B, C, D, E, F, 
G, H, respectively） in the BAL fluid of patients with 
UIP, NSIP, CVD-IP （RA）, CVD-IP （DM）, and sarcoi-
dosis. IL-2 was significantly （P＜0.05） higher in sar-
coidosis than in UIP. Furthermore, there were no sig-
nificant differences between NSIP, CVD-IP （RA）, and 
CVD-IP （DM）. Levels of IL-6 tended to be high for 
CVD-IP （RA） and DM, compared with UIP, NSIP, and 
sarcoidosis. Levels of IL-7 were significantly （P＜0.05） 
higher in CVD-IP （DM） than in CVD-IP （RA）. In ad-
dition, there were no significant differences between 
UIP, NSIP, and sarcoidosis. Levels of IL-8 tended to be 
high for CVD-IP （RA）, compared with UIP, NSIP, 
CVD-IP （DM）, and sarcoidosis. IL-17 was detected in 
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????????　 BAL fluid levels of IL-2, -6, -7, -8, -17, IFN-g , TNF-a , and TGF-b 1（Figure 1 ?, ?, ?, ?, ?, ?, ?, ?, 
respectively）in patients with UIP, NSIP, CVD-IP（RA）, CVD-IP（DM）, and sarcoidosis. IL-2, -6, -7, -8, -17, 
IFN-g , and TNF-a  were measured using a bead suspension array. Detection limits were 0.2 pg/ml, respectively. 
Concentrations of TGF-b 1 were measured using ELISA kits, and the detection limit was 31.2 pg/ml. Data are 
presented as mean±SD values. P＜0.05, compared with each IPs.CVD-IP：collagen vascular disease associated 
with interstitial pneumonia；NSIP：nonspecific interstitial pneumonia；UIP：usual interstitial pneumonia；RA：
rheumatoid arthritis；DM：dermatomyositis.
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CVD-IP （RA） and in a part of CVD-IP （DM）. Levels 
of IL-17 were significantly （P＜0.05） higher in CVD-
IP （RA） than in CVD-IP （DM）. Levels of IFN-g  
showed no significant differences among IPs and sar-
coidosis. Levels of TNF-a  tended to be high for CVD-
IP （RA） compared with UIP, NSIP, CVD-IP （DM）, 
and sarcoidosis. Levels of TGF-b 1 were detected in 3 
patients with sarcoidosis but not with UIP, NSIP, 
CVD-IP （RA）, or CVD-IP （DM）.
Correlation between cytokine levels and cell type in 
BAL fluid
IL-2, -6, -7, -8, -17, IFN-g , TNF-a , and TGF-b 1 
are produced by macrophages, lymphocytes, and neu-
trophils in the lung, and by other cells such as fibro-
blasts and epithelial cells. We analyzed the correlation 
between cytokine levels and cell type in BAL fluid us-
ing Spearman’s rank correlation （Table 2）. TNF-a  in 
NSIP and UIP was significantly （P＜0.05） correlated 
with neutrophils （Table 2）. In addition, the correlation 
between cell type and IL-7 in CVD-IP （DM）, IL-17 in 
CVD-IP （RA）, or IL-2 in sarcoidosis are shown in Fig-
ure 2 . There were no correlations between each cell 
type and IL-17 in CVD-IP （RA） （Figure 2A）, or IL-2 
in sarcoidosis （Figure 2C）. And IL-7 in CVD-IP （DM） 
was significantly （P＜0.05） correlated with lympho-
cytes （Table 2 and Figure 2B）. No correlations were 
noted between serological results （LDH, KL-6 , and 
SPD） and cell type and cytokines （data not shown）.
??????????
Here, we analyzed the correlation between cell sub-
populations and cytokines in BAL fluid of patients with 
UIP, NSIP, CVD-IP （RA）, CVD-IP （DM）, and sarcoi-
dosis. Occasionally, it is difficult for clinical discrimina-
tion between UIP and NSIP. In our results and several 
reports20,21）, the subpopulations of lymphocytes in BAL 
may play an important clinically discrimination be-
tween UIP and NSIP but the pattern of cytokines 
could not be unclear. In addition, the involvement of 
any cytokines, such as IL-8, IL-17, and TNF-a  has in-
dicated in RA22,23）. And also, the cytokines pattern of 
BAL was similar in CVD-IP （RA）, but not in CVD-IP 
（DM）. Thus, we clearly showed the different patho-
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???????　Correlation between cytokines and differential cell counts.
Sperman’srank correlation
IL-2 IL-6 IL-7 IL-8 IL-17 IFN-g TNF-a TGF-b
UIP Macrophages（％）
Lymphocytes（％）
Neutrophils（％）
Eosinophils（％）
−0.5643
　0.5643
　0.6669
　0.1539
−0.5000
　0.1000
　0.1000
−0.4000
　0.3000　
　0.1000　
−0.1000　
　0.1000　
−0.1000　
−0.1000＊
　0.2000　
　0.7000　
N.D
N.D
N.D
N.D
−0.9000＊
−0.3000　
　0.7000　
　0.3000　
−1.0000＊
−0.1000　
　0.9000＊
　0.4000　
N.D
N.D
N.D
N.D
NSIP Macrophages（％）
Lymphocytes（％）
Neutrophils（％）
Eosinophils（％）
−0.0920
　0.0552
−0.0309
　0.0615
−0.1030
　0.0182
　0.4024
　0.1228
　0.2492　
−0.3769　
　0.1132　
−0.3696　
　0.2000　
−0.1515　
　0.3293　
−0.2004　
N.D
N.D
N.D
N.D
　0.2392　
−0.5836　
−0.1626　
−0.0713　
−0.2485　
　0.1394　
　0.7195＊
　0.3951　
N.D
N.D
N.D
N.D
CVD-IP
（RA）
Macrophages（％）
Lymphocytes（％）
Neutrophils（％）
Eosinophils（％）
−0.1316
　0.2052
−0.6669
　0.6669
　0.6669
−0.8000
−0.5000
　0.3000
　0.4104　
−0.5000　
−0.7000　
　0.6000　
　0.1539　
−0.4000　
−0.3000　
　0.1000　
−0.5000
−0.1539
　0.4104
−0.0531
−0.1026　
　0.1000　
−0.3000　
　0.6000　
−0.3591　
−0.4000　
　0.8000　
−0.6000　
N.D
N.D
N.D
N.D
CVD-IP
（DM）
Macrophages（％）
Lymphocytes（％）
Neutrophils（％）
Eosinophils（％）
−0.1000
−0.1000
−0.4000
−0.2000
−0.3000
　0.5000
−0.8000
−0.6000
　0.1000　
　0.9000＊
−0.6000　
−1.0000　
　0.2000　
　0.3000　
−0.7000　
−0.5000　
　0.7071
−0.3536
　0.0000
N.D
−0.3000　
　0.5000　
−0.8000　
−0.6000　
−0.3000　
　0.7000　
−0.7000　
−0.6000　
N.D
N.D
N.D
N.D
Sarcoi-
dosis
Macrophages（％）
Lymphocytes（％）
Neutrophils（％）
Eosinophils（％）
　0.1628
−0.2706
　0.3334
−0.1943
　0.0198
−0.1209
　0.4054
　0.2580
−0.0022　
−0.0946　
　0.1483　
−0.3488　
　0.0330　
　0.0198　
　0.3742　
−0.4212　
N.D
N.D
N.D
N.D
−0.1236　
　0.0000　
　0.4370　
−0.0629　
−0.1868　
　0.0769　
　0.3567　
　0.1117　
−0.3272
　0.3762
−0.2975
　0.2393
＊P＜0.05. N.D；not detect.
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genesis of lung lesions between RA and DM.
IIP are a heterogeneous group of diffuse parenchy-
mal lung diseases of unknown etiology24）. Because of 
differences in clinical manifestation, radiographic fea-
tures, and prognosis, different types of IIP are classi-
fied into seven histopathologic entities that include UIP 
and NSIP24）. Separating NSIP from UIP is important 
because NSIP has better prognosis than UIP25）. BAL is 
a non-invasive diagnostic procedure in interstitial lung 
diseases （ILD）26,27）. In patients suspected to have UIP 
or NSIP, analysis of differential white blood cell counts 
in BAL fluid can be helpful. In the past, BAL lympho-
cytosis was considered a good prognostic factor while 
BAL neutrophilia or eosinophilia denoted poor clinical 
outcome in patients with UIP20）. Since NSIP was first 
described in 1994 , BAL lymphocytosis is more likely 
suggestive of NSIP rather than UIP21）. Similarly, we 
also found that the percentage of lymphocytes tended 
to be high for NSIP compared with UIP.
These findings indicate that evaluation of lympho-
cytes in BAL fluid is useful for distinguishing between 
UIP and NSIP. In some collagen diseases, RA is a sys-
temic disease process characterized by inflammation of 
the synovial tissues lining joints. Proliferation of syn-
ovial lining cells and infiltration of inflammatory cells, 
including monocytes and activated leukocytes, such as 
lymphocytes and neutrophils, into joint tissues results 
in proinflammatory factors that lead to destruction of 
both cartilage and bone matrix28）. Moreover, in DM, in-
flammatory infiltrates are composed primarily of mac-
??（3） （2012） 167
????????　 Correlation between cell type and IL-17 in 
CVD-IP（RA）（?）, IL-7 in CVD-IP （DM）（?）, 
or IL-2 in sarcoidosis （?）. R values were 
determined by linear regression analysis 
between each cell type and cytokines. CVD-
IP：collagen vascular disease associated with 
interstitial pneumonia；NSIP：nonspecific 
interstitial pneumonia；UIP：usual interstitial 
pneumonia；RA：rheumatoid arthritis；DM：
dermatomyositis.
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rophages, B cells, and CD4＋ cells in the perivascular 
and perimysial regions29,30）. Infiltration of these inflam-
matory cells into skin and muscle develops in the 
pathogenesis of DM. However, the pathogenesis of in-
terstitial pneumonia in patients with RA and DM re-
mains poorly understood. We found that the population 
of neutrophils was highest for CVD-IP （RA）, com-
pared with other IPs, CVD-IP （DM）, and sarcoidosis. 
On the other hand, there were no significant differenc-
es of BAL cells in CVD-IP （DM） compared with BAL 
findings of healthy subjects 31）. These results suggest 
that neutrophils in CVD-IP （RA） and lymphocytes 
and macrophages in CVD-IP （DM） may play an im-
portant role in the development of interstitial pneumo-
nia.
Although the pathogenesis of sarcoidosis has not 
been elucidated, many observations, including the pres-
ence of oligoclonal T cells in BAL fluid, blood, and skin 
granulomas, are suggestive of an antigen-driven auto-
immune disease32,33）. Similarly, we also found that the 
population of lymphocytes, but not that of neutrophils 
and macrophages, was highest for sarcoidosis, com-
pared with other IPs. The results indicate that lym-
phocytes play an important role in the pathogenesis of 
sarcoidosis. On the basis of these findings, biological 
studies of interstitial lung disease have detected sever-
al cell types that are differentially expressed in pa-
tients with IIPs and CVD-IP.
Inflammatory cytokines and chemokines have been 
reported to play important roles in the pathogenesis of 
interstitial lung diseases 34,35）. Table 3 shows the pat-
tern of each cytokines and chemokines among IIPs, 
CVD-IP, and sarcoidosis. Monocyte chemoattractant 
protein （MCP）-1 is closely associated with the expres-
sion of adhesion molecules and the migration of inflam-
matory cells into the lung, and Yoshioka et al 35） sug-
gested that MCP- 1 in BAL fluid may play an 
important role in inflammatory cell recruitment to the 
lung in NSIP compared with UIP. An association be-
tween lymphocytosis and IL-6 levels in BAL fluid of 
patients with NSIP has also been reported36）. Our re-
sults showed that the levels of MCP-1 （data not 
shown） and IL-6 did not differ between UIP and NSIP. 
This discrepancy can be attributed to differences in 
the activity and severity of NSIP, as well as the timing 
of BAL. It is widely accepted that TGF-b 1 might play 
an important role in the pathogenesis of lung injury 
such as UIP and NSIP. TGF-b 1 is produced by lym-
phocytes, macrophages, and fibroblasts in the lung and 
is considered a critical mediator of pathological, fibrot-
ic, and remodeling responses in the lung and other or-
gans, and such responses are thought to be mediated 
by the ability of TGF-b 1 to active fibrogenic and 
apoptotic injury pathways37〜39）. In our study however, 
no TGF-b 1 was detected in UIP, NSIP, or CVD-IP. 
This may be due to the low measurement sensitivity 
for TGF-b 1 using the ELISA kit.
In DM, the primary cellular sources of cytokines are 
immune cells, but endothelial cells and muscle fibers 
can also express these immune regulators40）. The im-
portant role of TNF as a regulator of chronic inflam-
mation associated with DM has previously been estab-
lished41,42）. IL-1b  is significantly upregulated in DM43）. 
Our results showed no differences in the levels of IL-
1b  （data not shown） and TNF-a  between CVD-IP 
（DM） and other IPs. The discrepancy was considered 
to be due to differences in pathogenesis between lung 
lesions and other organs, such as skin and muscle, and 
disease activity. Levels of IL-7 were higher in CVD-IP 
（DM） than in CVD-IP （RA）. IL-7 is a growth factor 
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???????　 The expression of each cytokines in UIP, NSIP, CVD-IP （RA）, CVD-IP （DM）, and 
sarcoidosis
IL-2 IL-6 IL-7 IL-8 IL-17 IFN-g TNF-a TGF-b
UIP ＋ ＋ ＋＋ ＋ − ＋ ± −
NSIP ＋ ＋ ＋＋ ＋ − ＋ ± −
CVD-IP （RA） ＋＋ ＋＋ ＋ ＋＋ ＋＋＋ ＋＋ ＋＋ −
CVD-IP （DM） ＋＋ ＋＋ ＋＋＋ ＋ ＋ ＋＋ ＋ −
Sarcoi-dosis ＋＋＋ ＋ ＋ ± − ＋ ＋ ＋
BAL fluid in patients with interstitial pneumonia
of not only lymphocytes but also fibroblasts through 
the receptor IL-7R44,45）. Therefore, these inflammable 
cells may be involved in the development of lung in-
flammation and fibrosis.
In RA, synovial tissue in inflamed joints infiltrated 
with activated macrophages and leukocytes is a rich 
source of pro-inflammatory cytokines, including TNF-
a , IL-1, IL-6 and IL-17, that impact bone remodeling 
within the RA bone microenvironment22）. TNF-a  in-
duces the production of other proinflammatory cytok-
ines （IL-1, IL-6, IL-8）23） and is synthesized mainly by 
macrophages and activated T cells. IL-6 is a pleiotro-
pic proinflammatory cytokine produced by a variety of 
cell types in the inflamed RA bone microenvironment 
including macrophages and fibroblast-like synovio-
cytes46）. IL-6 as an important effector of inflammation-
induced joint destruction in arthritis is supported by 
the observation that mice deficient in IL-6 were pro-
tected against bone destruction in an antigen-induced 
arthritis model 47）. IL-8 is a chemokine produced by 
macrophages and other cell types such as epithelial 
cells and endothelial cells 48）. The primary function of 
IL-8 is the induction of chemotaxis in neutrophils49）. 
We showed that the levels of IL-6, IL-8, and TNF-a  
tended to be higher in CVD-IP （RA） than in other 
IPs. Our results indicate that these cytokines may play 
an important role in the pathogenesis of lung lesions in 
RA. In addition, there were no correlations between 
these cytokines and BAL cell populations, suggesting 
that these cytokines correlate with lung fibroblasts 
and/or epithelial cells. IL-17 acts as a potent mediator 
in delayed-type reactions by increasing chemokine 
production in various tissues to recruit monocytes and 
neutrophils to the site of inflammation50）. Interestingly, 
IL-17 levels were detectable only in CVD-IP （RA） 
and in a part of CVD-IP （DM）, but not in UIP, NSIP, 
or sarcoidosis. Moreover, IL-17 did not correlate with 
the positive results of rheumatoid factors in patients 
with other UIP and NSIP （data not shown）. These 
findings suggest that IL-17 may be a specific biomark-
er of CVD-IP （RA）.
Th1 cells, and their products IL-2 and IFN-g , are 
thought to be involved in the pathogenesis of sarcoido-
sis 51）. We found that the levels of IL-2 tended to be 
higher in sarcoidosis than in other IPs. On the other 
hand, IFN-g  levels were consistent across these IPs. 
This could be because IFN-g  also plays an important 
role in the pathogenesis of not only sarcoidosis but also 
other IPs. Pulmonary fibrosis develops in approximate-
ly 25％ of patients with chronic sarcoidosis52）. There-
fore, high levels of TGF-b 1 in the 3 patients with sar-
coidosis may develop in lung fibrosis in the near 
future.
We found the correlations between IL-7 and lym-
phocytes in CVD-IP （DM）. IL-7 is secreted by strom-
al cells in red marrow and the thymus, and it is also 
produced by keratinocytes, dendritic cells, hepatocytes, 
neurons, and epithelial cells but is not produced by 
lymphocytes53〜56）. Accordingly, IL-7 might be involved 
in the proliferation of lymphocytes and lung fibroblasts 
through IL-7 R in CVD-IP （DM）. In addition, IL-17 
plays an important role in pathogenesis of CVD-IP 
（RA）. IL-17 is produced by T helper cells, and recruit 
neutrophils into various tissues. In our results, there 
was no correlation between IL-17 , lymphocytes, and 
neutrophils. This discrepancy was thought to be due 
to the differences between the amount of IL-17 and its 
responsibility to neutrophils, and between the number 
of IL-17-producing cells and its amount from a cell in 
individual patients. IL-2 plays an important role in the 
pathogenesis of sarcoidosis. IL-2 is produced by Th1 
cells and proliferated by lymphocytes through its re-
ceptor IL-2 R57）, while IFN-g  is produced by Th1 cells 
and macrophages and has antiviral, immunoregulatory, 
and anti-tumor properties58）. In our results, there was 
no correlation between IL-2 and lymphocytes, possibly 
because of the differences between the amount of IL-2 
and its responsibility to lymphocytes in individual pa-
tients.
Although the pattern of cell types, cytokines, and 
chemokines tended to differ between IIPs and CVD-
IPs, it was difficult to find clearly the disease specific 
biomarker except IL-17 in CVD-IP （RA）. The find-
ings were thought to be because of the small number 
of the diseases and/or the activity. We comprehensive-
ly considered that BAL may be useful for not only di-
agnosing a variety of specific CVD-IPs but also nar-
rowing the differential diagnosis and predicting 
prognosis in fibrotic IIP, such as NSIP and UIP. There-
fore, BAL should be performed in IIP and CVD-IP 
whenever possible. A long-term prospective study is 
needed to define the role of BAL more clearly in IIP 
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and CVD-IP.
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